Pharmacologic Treatments with Lifestyle Modifications in Nonpregnant Adults with Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline from the American College of Physicians

ACP issues clinical guidelines to help physicians choose medications with lifestyle modifications to manage overweight and obesity in adults.

ACP issues clinical guidelines to help physicians choose medications with lifestyle modifications to manage overweight and obesity in adults.

Reyna Howkins

clinical guideline; guideline; living clinical guideline; living guideline policy; recommendations; overweight; obesity; pharmacologic treatments; medication; health care; provision of care; first-line treatment; second-line treatment; semaglutide; tirzepatide; phentermine-topiramate; liraglutide; naltrexone-bupropion; weight management; comorbid conditions; comorbidity; lifestyle modifications; weight loss; obesity medications; weight-loss drugs

Tue, 06/09/2026 - 9:54 AM EDT

Tue, 06/09/2026 - 9:55 AM EDT

1

pharmacologic_treatments_in_nonpregnant_adults_with_overweight_or_obesity_outpatient_2026.pdf

{"Author":"Reyna Howkins","CreationDate":"2026-06-09T09:54:15-04:00","Creator":"Microsoft\u00ae Word for Microsoft 365","Keywords":"clinical guideline; guideline; living clinical guideline; living guideline policy; recommendations; overweight; obesity; pharmacologic treatments; medication; health care; provision of care; first-line treatment; second-line treatment; semaglutide; tirzepatide; phentermine-topiramate; liraglutide; naltrexone-bupropion; weight management; comorbid conditions; comorbidity; lifestyle modifications; weight loss; obesity medications; weight-loss drugs","ModDate":"2026-06-09T09:55:04-04:00","Producer":"Microsoft\u00ae Word for Microsoft 365","Subject":"ACP issues clinical guidelines to help physicians choose medications with lifestyle modifications to manage overweight and obesity in adults.","Title":"Pharmacologic Treatments with Lifestyle Modifications in Nonpregnant Adults with Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline from the American College of Physicians","Pages":1,"pdf:producer":"Microsoft\u00ae Word for Microsoft 365","pdf:keywords":"clinical guideline; guideline; living clinical guideline; living guideline policy; recommendations; overweight; obesity; pharmacologic treatments; medication; health care; provision of care; first-line treatment; second-line treatment; semaglutide; tirzepatide; phentermine-topiramate; liraglutide; naltrexone-bupropion; weight management; comorbid conditions; comorbidity; lifestyle modifications; weight loss; obesity medications; weight-loss drugs","xmp:creatortool":"Microsoft\u00ae Word for Microsoft 365","xmp:createdate":"2026-06-09T09:54:15-04:00","xmp:modifydate":"2026-06-09T09:55:04-04:00","xmp:metadatadate":"2026-06-09T09:55:04-04:00","xmpmm:documentid":"uuid:05AE64DE-E4A5-4129-A0FE-C103A4C89921","xmpmm:instanceid":"uuid:ebd0c36f-08c3-42a4-86c9-1a518887d0b3","dc:format":"application\/pdf","dc:creator":"Reyna Howkins","dc:title":"Pharmacologic Treatments with Lifestyle Modifications in Nonpregnant Adults with Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline from the American College of Physicians","dc:subject":["clinical guideline","guideline","living clinical guideline","living guideline policy","recommendations","overweight","obesity","pharmacologic treatments","medication","health care","provision of care","first-line treatment","second-line treatment","semaglutide","tirzepatide","phentermine-topiramate","liraglutide","naltrexone-bupropion","weight management","comorbid conditions","comorbidity","lifestyle modifications","weight loss","obesity medications","weight-loss drugs"],"dc:description":"ACP issues clinical guidelines\u00a0to help physicians choose medications with lifestyle modifications to manage overweight and obesity in adults."}

2026